Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4689

1.

Chemically modified antisense oligonucleotide against ARL4C inhibits primary and metastatic liver tumor growth.

Harada T, Matsumoto S, Hirota S, Kimura H, Fujii S, Kasahara Y, Gon H, Yoshida T, Itoh T, Haraguchi N, Mizushima T, Noda T, Eguchi H, Nojima S, Morii E, Fukumoto T, Obika S, Kikuchi A.

Mol Cancer Ther. 2019 Jan 15. pii: molcanther.0824.2018. doi: 10.1158/1535-7163.MCT-18-0824. [Epub ahead of print]

PMID:
30647122
2.

The Rolipram-Perillyl Alcohol Conjugate (NEO214) Is A Mediator Of Cell Death Through The Death Receptor Pathway.

Cho HY, Thein TZ, Wang W, Swenson SD, Fayngor RA, Ou M, Marín-Ramos NI, Schönthal AH, Hofman FM, Chen TC.

Mol Cancer Ther. 2019 Jan 15. pii: molcanther.0465.2018. doi: 10.1158/1535-7163.MCT-18-0465. [Epub ahead of print]

PMID:
30647121
3.

Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP.

Liu H, Qin Y, Zhai D, Zhang Q, Gu J, Tang Y, Yang J, Li K, Yang L, Chen S, Zhong W, Meng J, Liu Y, Sun T, Yang C.

Mol Cancer Ther. 2019 Jan 14. pii: molcanther.0936.2018. doi: 10.1158/1535-7163.MCT-18-0936. [Epub ahead of print]

PMID:
30642883
4.

Blood Interactions, Pharmacokinetics and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin.

Carter KA, Luo D, Geng J, Stern ST, Lovell JF.

Mol Cancer Ther. 2018 Dec 26. pii: molcanther.0549.2018. doi: 10.1158/1535-7163.MCT-18-0549. [Epub ahead of print]

PMID:
30587558
5.

TSR-033, a novel therapeutic antibody targeting LAG-3 enhances T cell function and the activity of PD-1 blockade in vitro and in vivo.

Ghosh S, Sharma G, Travers J, Kumar S, Choi J, Jun HT, Kehry M, Ramaswamy S, Jenkins D.

Mol Cancer Ther. 2018 Dec 26. pii: molcanther.0836.2018. doi: 10.1158/1535-7163.MCT-18-0836. [Epub ahead of print]

PMID:
30587557
6.

TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer.

Principe DR, Park A, Dorman MJ, Kumar S, Viswakarma N, Rubin J, Torres C, McKinney R, Munshi HG, Grippo PJ, Rana A.

Mol Cancer Ther. 2018 Dec 26. pii: molcanther.0850.2018. doi: 10.1158/1535-7163.MCT-18-0850. [Epub ahead of print]

PMID:
30587556
7.

Enhancing chemosensitivity of breast cancer stem cells by down regulating SOX2 and ABCG2 using Wedelolactone-encapsulated nanoparticles.

Das S, Mukherjee P, Chatterjee R, Jamal Z, Chatterji U.

Mol Cancer Ther. 2018 Dec 26. pii: molcanther.0409.2018. doi: 10.1158/1535-7163.MCT-18-0409. [Epub ahead of print]

PMID:
30587555
8.

Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in new onset metastatic castration-resistant prostate cancer (mCRPC).

Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N.

Mol Cancer Ther. 2018 Dec 26. pii: molcanther.0739.2018. doi: 10.1158/1535-7163.MCT-18-0739. [Epub ahead of print]

PMID:
30587554
9.

The secretome engages STAT3 to favor a cytokine-rich microenvironment in mediating acquired resistance to FGFR inhibitors.

Wang X, Ai J, Liu H, Peng X, Chen H, Chen Y, Su Y, Shen A, Huang X, Ding J, Geng M.

Mol Cancer Ther. 2018 Dec 6. pii: molcanther.0179.2018. doi: 10.1158/1535-7163.MCT-18-0179. [Epub ahead of print]

PMID:
30523050
10.

Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients.

Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R.

Mol Cancer Ther. 2018 Dec 6. pii: molcanther.0535.2018. doi: 10.1158/1535-7163.MCT-18-0535. [Epub ahead of print]

PMID:
30523049
11.

KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations.

Liu X, Zhang SM, McGeary MK, Krykbaeva I, Lai L, Jansen DJ, Kales SC, Simeonov A, Hall MD, Kelly DP, Bosenberg MW, Yan Q.

Mol Cancer Ther. 2018 Dec 6. pii: molcanther.0395.2018. doi: 10.1158/1535-7163.MCT-18-0395. [Epub ahead of print]

PMID:
30523048
12.

Combined PPARg Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors.

Leung DTH, Nguyen T, Oliver EM, Matti J, Alexiadis M, Silke J, Jobling TW, Fuller PJ, Chu S.

Mol Cancer Ther. 2018 Dec 7. pii: molcanther.0078.2018. doi: 10.1158/1535-7163.MCT-18-0078. [Epub ahead of print]

PMID:
30530769
13.

Cooperative effect of oncogenic MET and PIK3CA in an HGF-dominant environment in breast cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2018 Dec 5. pii: molcanther.0710.2018. doi: 10.1158/1535-7163.MCT-18-0710. [Epub ahead of print]

PMID:
30518672
14.

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.

Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, Sharma S, Lee J, Shacham S, Landesman Y, Maltsev N, Lu P, Wang YL.

Mol Cancer Ther. 2018 Dec;17(12):2564-2574. doi: 10.1158/1535-7163.MCT-17-0789-ATR.

PMID:
30510142
15.

Targeting the sphingosine 1-phosphate axis exerts potent antitumor activity in BRAFi-resistant melanomas.

Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Segui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N.

Mol Cancer Ther. 2018 Nov 27. pii: molcanther.1141.2017. doi: 10.1158/1535-7163.MCT-17-1141. [Epub ahead of print]

PMID:
30482853
16.

Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma.

Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Karni R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.

Mol Cancer Ther. 2018 Nov 27. pii: molcanther.0456.2018. doi: 10.1158/1535-7163.MCT-18-0456. [Epub ahead of print]

PMID:
30482852
17.

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2018 Nov 26. pii: molcanther.0537.2018. doi: 10.1158/1535-7163.MCT-18-0537. [Epub ahead of print]

PMID:
30478151
18.

Targeting of BRM sensitizes BRG1 mutant lung cancer cell lines to radiotherapy.

Zernickel E, Sak A, Riaz A, Klein D, Groneberg M, Stuschke M.

Mol Cancer Ther. 2018 Nov 26. pii: molcanther.0067.2018. doi: 10.1158/1535-7163.MCT-18-0067. [Epub ahead of print]

PMID:
30478150
19.

3D growth of cancer cells elicits sensitivity to kinase inhibitors but not lipid metabolism modifiers.

Jones DT, Valli A, Haider S, Zang Q, Smethurst E, Schug ZT, Peck B, Aboagye EO, Critchlow SE, Schulze A, Gottlieb E, Wakelam MJO, Harris AL.

Mol Cancer Ther. 2018 Nov 26. pii: molcanther.0857.2018. doi: 10.1158/1535-7163.MCT-17-0857. [Epub ahead of print]

PMID:
30478149
20.

Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors.

Pham TND, Kumar K, DeCant BT, Shang M, Munshi SZ, Matsangou M, Ebine K, Munshi HG.

Mol Cancer Ther. 2018 Nov 16. doi: 10.1158/1535-7163.MCT-18-0768. [Epub ahead of print]

PMID:
30446586

Supplemental Content

Loading ...
Support Center